<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00160368</url>
  </required_header>
  <id_info>
    <org_study_id>CH/FR/04.0012</org_study_id>
    <nct_id>NCT00160368</nct_id>
  </id_info>
  <brief_title>Effects of Potassium Salts on Blood Pressure and Target Organ Damage</brief_title>
  <official_title>Effect of Potassium Bicarbonate and Potassium Chloride on Blood Pressure and Markers of Target Organ Damage in Hypertensives</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St George's, University of London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St George's, University of London</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effect of potassium chloride and potassium&#xD;
      bicarbonate on blood pressure and also to determine whether increasing potassium intake has&#xD;
      beneficial effects on the surrogate markers of target organ damage in cardiovascular disease,&#xD;
      as well as on bone health.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomised trials have shown that increasing potassium intake lowers blood pressure. However,&#xD;
      most previous trials used potassium chloride. Whereas, potassium in fruits and vegetables is&#xD;
      not a chloride salt, but a mixture of potassium phosphate, sulphate, citrate, and many&#xD;
      organic anions, most of which are precursors of potassium bicarbonate. It is unclear whether&#xD;
      non-chloride salt of potassium has greater or lesser effect on blood pressure compared to&#xD;
      potassium chloride.&#xD;
&#xD;
      Experimental studies in animals and epidemiological studies in humans suggest that a high&#xD;
      potassium intake may have beneficial effects on the cardiovascular system and the kidney,&#xD;
      independent of its effect on blood pressure, and also reduce the risk of osteoporosis.&#xD;
&#xD;
      We propose to carry out a randomised double-blind trial to compare potassium bicarbonate with&#xD;
      potassium chloride looking at their effect on blood pressure, and also to determine whether&#xD;
      these potassium salts have beneficial effects on the cardiovascular system, kidney and bone&#xD;
      health.&#xD;
&#xD;
      Comparisons: potassium chloride vs potassium bicarbonate vs placebo.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2005</start_date>
  <completion_date type="Anticipated">March 2008</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood pressure and markers of target organ damage and bone health at 4 weeks of potassium supplementation.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparisons among different treatments in blood pressure and markers of target organ damage and bone health.</measure>
  </secondary_outcome>
  <enrollment>45</enrollment>
  <condition>Hypertension</condition>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Potassium supplementation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with untreated essential hypertension (sitting systolic blood pressure&#xD;
             between 140 and 170 mmHg and/or sitting diastolic blood pressure between 90 and 105&#xD;
             mmHg);&#xD;
&#xD;
          -  Age 18 - 75 years.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Individuals younger than 18 or older than 75 years;&#xD;
&#xD;
          -  Individuals with impaired renal function with plasma creatinine greater than 120&#xD;
             umol/L for non-blacks or 150 umol/L for blacks;&#xD;
&#xD;
          -  Individuals with chronic diarrhea, or history of peptic ulcer;&#xD;
&#xD;
          -  Individuals with baseline plasma potassium values greater than 5.0 mmol/L;&#xD;
&#xD;
          -  Individuals with severe hypertension i.e. blood pressure &gt; 170/105 mmHg;&#xD;
&#xD;
          -  Individuals with diabetes mellitus;&#xD;
&#xD;
          -  Individuals with any secondary cause of hypertension;&#xD;
&#xD;
          -  Individuals with malignancy or liver disease;&#xD;
&#xD;
          -  Individuals with ischaemic heart disease or heart failure;&#xD;
&#xD;
          -  Females who are pregnant or breast feeding or on the oral contraceptive pill.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Graham A MacGregor, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St George's, University of London</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Feng J He, PhD</last_name>
    <phone>0044-20-8725-5375</phone>
    <email>fhe@sgul.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Graham A MacGregor, MD</last_name>
    <phone>0044-20-8725-5774</phone>
    <email>gmacgregor@sgul.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>St. George's University of London,</name>
      <address>
        <city>London</city>
        <zip>SW17 0RE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Feng J He, PhD</last_name>
      <phone>0044-20-8725-5375</phone>
      <email>fhe@sgul.ac.uk</email>
    </contact>
    <contact_backup>
      <last_name>Graham A MacGregor, MD</last_name>
      <phone>0044-20-8725-5774</phone>
      <email>gmacgregor@sgul.ac.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Feng J He, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Graham A MacGregor, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2007</verification_date>
  <study_first_submitted>September 8, 2005</study_first_submitted>
  <study_first_submitted_qc>September 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2005</study_first_posted>
  <last_update_submitted>April 24, 2007</last_update_submitted>
  <last_update_submitted_qc>April 24, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 25, 2007</last_update_posted>
  <keyword>Hypertension, potassium salts</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

